EUVIMEDEUVIMED entdecken
Open Access

Prostate Cancer Screening Uptake in Transgender Women

Sandhya Kalavacherla, Paul Riviere, Sruthi Kalavacherla, Jennifer T Anger, James D Murphy, Brent S Rose

JAMA Network Open · 14.02.2024 · 7 (2) · e2356088

DOI: 10.1001/jamanetworkopen.2023.56088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 14.02.2024. Verfasst von Sandhya Kalavacherla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Transgender Persons. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There is no consensus in prostate-specific antigen (PSA) screening guidelines regarding transgender women despite their known prostate cancer risk.

Objective

To identify factors associated with recent (within the last 2 years) PSA screening in transgender women compared with cisgender men. Design, Setting, and Participants This case-control study used data from the 2018 and 2020 Behavioral Risk Factor Surveillance System (BRFSS) surveys to characterize rates of PSA screening for prostate cancer within the past 2 years and multivariable logistic regressions to characterize factors associated with recent screening among transgender women. The BRFSS program of the Centers for Disease Control and Prevention annually surveys over 400 000 US adults on behavioral risk factors, chronic illnesses, and use of preventive services. Respondents to the BRFSS who were cisgender men or transgender women 40 years or older and who had complete PSA testing responses and no prostate cancer history were included; 313 transgender women and 138 937 cisgender men met inclusion criteria. Matching was performed by age, race and ethnicity, educational level, employment, annual income, survey year, and cost barriers to care. Data were collected on November 2, 2022, and analyzed from November 2, 2022, to December 3, 2023. Main Outcomes and Measures Rates of and factors associated with recent PSA screening in transgender women.

Results

Among the 1275 participants included in the matched cohort (255 transgender women and 1020 cisgender men; 570 [44.7%] aged 55-69 years), recent PSA screening rates among transgender women and cisgender men aged 55 to 69 were 22.2% (n = 26) and 36.3% (n = 165), respectively; among those 70 years and older, these rates were 41.8% (n = 26) and 40.2% (n = 98), respectively. In the matched cohort, transgender women had lower univariable odds of recent screening than cisgender men (odds ratio [OR], 0.65 [95% CI, 0.46-0.92]; P = .02). In a hierarchical regression analysis adding time since the last primary care visit, effect size and significance were unchanged (OR, 0.61 [95% CI, 0.42-0.87]; P = .007). After adding whether a clinician recommended a PSA test, there was no statistically significant difference in odds of screening between transgender women and cisgender men (OR, 0.83 [95% CI, 0.45-1.27]; P = .21). The results were further attenuated when clinician-led discussions of PSA screening advantages and disadvantages were added (OR, 0.87 [95% CI, 0.47-1.31]; P = .32). In a multivariable logistic regression among transgender women, having a recommendation for PSA testing was the factor with the strongest association with recent screening (OR, 12.40 [95% CI, 4.47-37.80]; P < .001). Conclusions and Relevance In this case-control study of one of the largest cohorts of transgender women studied regarding PSA screening, the findings suggest that access to care or sociodemographic factors were not principal drivers of the screening differences between transgender women and cisgender men; rather, these data underscore the clinician’s role in influencing PSA screening among transgender women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsTransgender PersonsUnited StatesAdultMaleHumansEarly Detection of CancerProstate-Specific AntigenCase-Control StudiesPathologic Complete ResponseFemale

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla.
  • Center for Health Equity, Education, and Research, University of California, San Diego, La Jolla.
  • Department of Biology, Massachusetts Institute of Technology, Cambridge.
  • Department of Urology, University of California, San Diego, La Jolla.

Zitieren

APA

Kalavacherla, S., Riviere, P., Kalavacherla, S., Anger, J. T., Murphy, J. D., & Rose, B. S. (2024). Prostate Cancer Screening Uptake in Transgender Women. JAMA Network Open, 7(2), e2356088. https://doi.org/10.1001/jamanetworkopen.2023.56088

Vancouver

Kalavacherla S, Riviere P, Kalavacherla S, Anger JT, Murphy JD, Rose BS. Prostate Cancer Screening Uptake in Transgender Women. JAMA Network Open. 2024;7(2):e2356088. doi:10.1001/jamanetworkopen.2023.56088

BibTeX
@article{Kalavacherla2024,
  author = {Kalavacherla, Sandhya and Riviere, Paul and Kalavacherla, Sruthi and Anger, Jennifer T and Murphy, James D and Rose, Brent S},
  title = {Prostate Cancer Screening Uptake in Transgender Women},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {2},
  pages = {e2356088},
  doi = {10.1001/jamanetworkopen.2023.56088}
}
Kostenlos starten →